MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days

Phase II Study of MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days

The Proseven trial is a phase II study that will evaluate the toxicity and efficacy of MR-guided stereotactic body radiotherapy (SBRT) in the profound hypofractionated treatment of prostate cancer. Patients will be treated in 5 daily fractions within a short overall treatment time (OTT) of 7 days. A simultaneous integrated boost (SIB) will be delivered to the intraprostatic dominant lesion (if present) in this study. Besides a potential biological impact of this innovative prostate SBRT treatment, the reduced OTT offers also benefits in terms of patient convenience. The primary endpoint is clinician reported grade 2 or more acute gastrointestinal (GI) and genitourinary (GU) toxicity, assessed using CTCAE v 5.0 and RTOG, measured up to 3 months after the first treatment fraction.

MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days

Recruitment

Summary

Participation Requirements

Description

Tracking Information